paediatrics Brussels 17

SIOP-HR-MB: Biology components

Upfront patient selection:

• •

Prognostic biomarkers

Upfront patient selection:

• •

Predictive biomarkers / targeted therapies*

Balance risk-factors across randomisation arms

•

Flexibility

•

Amendments as further risk-factors are validated

•

Targeted therapies as targets/biomarkers are validated

•

Comprehensive biological studies

•

As per SIOP-PNET5-MB infrastructure/plans

•

Studies across cohorts

•

Funding application submitted Q4 2017 outcome (UK/Sponsor)

• • •

2018 SIOPE partners